The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually RA'ANANA, Israel, Jan. 14, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is proud to announce the development of a modular configuration for its groundbreaking VORTX blood oxygenation delivery technology. We... Read more
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024.
Select Preliminary Financial Highlights
Fourth quarter 2024 total... Read more
First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators... Read more
MOUNTAIN VIEW, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended December 28, 2024.
Fourth Quarter 2024 Results The Company’s strategic review remains ongoing with multiple... Read more
NATICK, Mass. / Jan 14, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in... Read more
2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year
2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year
2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable... Read more
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included... Read more
National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national... Read more
The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 ACTON, Mass. / Jan 13, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available... Read more
GOLETA, Calif. / Jan 13, 2025 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024.
The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth... Read more
Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year
Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended... Read more
MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform and the introduction of the... Read more
Full-year 2024 total revenue grew 27% to approximately $611 million
Expect full-year 2025 total revenue of $732 million and positive free cash flow CARLSBAD, Calif. / Jan 13, 2025 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2024. The Company also provided a financial... Read more
Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%
Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024.
Fourth Quarter 2024 Summary (any comparisons... Read more
Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million
Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter... Read more
Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif., Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results.
Preliminary, Unaudited... Read more
Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar... Read more
Study demonstrates significant reductions in length of stay and healthcare costs, advocating for broader adoption of POCUS in hospital settings. BURLINGTON, Mass. & NEW YORK / Jan 13, 2025 / Business Wire / Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound today announced preliminary findings from a seminal study conducted by Rutgers Robert Wood Johnson Medical... Read more
Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. LATHAM, N.Y. / Jan 13, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality... Read more
ENGLEWOOD, Colo. / Jan 13, 2025 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024.
Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8 million, representing reported... Read more
MASON, Ohio / Jan 13, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason,... Read more
Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million QUEENSBURY, N.Y. / Jan 13, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024.
Preliminary Fourth Quarter... Read more
MAHWAH, N.J. / Jan 13, 2025 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024.
Financial Results (unaudited) Preliminary, unaudited fourth... Read more
Expects Record Revenues for the Fourth Quarter of 2024 SAN RAFAEL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the quarter ended December 31, 2024.
Total revenue for the fourth quarter of 2024 is estimated to be in the range of $5.0 million to $5.1 million, which is expected... Read more
PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results.
Highlights: Preliminary revenue... Read more
Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%
Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30%
Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited... Read more
CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024.
Preliminary Fourth Quarter 2024 Revenue Summary Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a... Read more
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission MIAMI / Jan 13, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA... Read more
VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline.
“We’re focused on finding... Read more
Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million
Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland / Jan 13, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working... Read more
Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems
Record U.S. Fourth Quarter Focal One System Sales
Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar... Read more
MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full year 2025 revenue guidance... Read more
VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven... Read more
ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024.
Preliminary Unaudited Fourth Quarter and Full Year 2024 Results Core revenue... Read more
Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds
Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that the Company closed the subscription... Read more
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier... Read more
BRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and revenue growth in the endovascular devices market.
Mr. Wilson’s career spans over 30 years and... Read more
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company’s Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025.
Ms. King is a seasoned healthcare executive with a proven track record... Read more
Peter Caldini to become Interim CEO effective March 1, 2025
Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance NEW YORK / Jan 13, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José... Read more
Revenue of $1,021.8 Million Grows 0.9%
Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance
GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges MARLBOROUGH, Mass. / Jan 12, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024.
The Company expects to report total revenues of approximately $1,021.8 million, an increase of 0.9% compared... Read more
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
Preliminary Unaudited Fourth Quarter and Full-year 2024 Results Preliminary unaudited fourth... Read more
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options.... Read more
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million
Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million
Iradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ:... Read more
First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue
Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time EDEN PRAIRIE, Minn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for... Read more
Current Co-Chairman of the Board will now also serve as Chief Executive Officer MIAMI / Jan 10, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.
"We are thrilled to have Paul... Read more
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials.
Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth... Read more
Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth
Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications
Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026
Combined cash position of approximately $175 million... Read more
SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at 3:45 p.m. PT. Management will also participate and... Read more
RA'ANANA, Israel, Jan. 10, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing need for advanced respiratory care... Read more
AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors.
“We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing... Read more
